Cochlear (Cochlear) Debt-to-Equity : 0.12 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Cochlear Debt-to-Equity?

Cochlear's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $27 Mil. Cochlear's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $112 Mil. Cochlear's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,193 Mil. Cochlear's debt to equity for the quarter that ended in Dec. 2023 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cochlear's Debt-to-Equity or its related term are showing as below:

CHEOF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12 Med: 0.3 Max: 0.72
Current: 0.12

During the past 13 years, the highest Debt-to-Equity Ratio of Cochlear was 0.72. The lowest was 0.12. And the median was 0.30.

CHEOF's Debt-to-Equity is ranked better than
63.9% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs CHEOF: 0.12

Cochlear Debt-to-Equity Historical Data

The historical data trend for Cochlear's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cochlear Debt-to-Equity Chart

Cochlear Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.25

0.50

0.16

0.15

0.12

Cochlear Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.15	0.15	0.15	0.12	0.12

Competitive Comparison of Cochlear's Debt-to-Equity

For the Medical Devices subindustry, Cochlear's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cochlear's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cochlear's Debt-to-Equity falls into.

Cochlear Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cochlear's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(26.309	+	109.128)	/	1173.691
	=	0.12

Cochlear's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(26.64	+	111.714)	/	1192.637
	=	0.12

Cochlear (OTCPK:CHEOF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cochlear Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cochlear's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cochlear (Cochlear) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cochlear Ltd (OTCPK:CHEOF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CHEOY:USA OC5:Germany COH:Australia

Address

1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109

Website

https://www.cochlear.com

Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.